Carbohydrate chemistry

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Natural sciences, Chemistry, Branches of biology, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Enzyme

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

Refined Functional Carbohydrates Market Worth $360 Million by 2027, Says Global Market Insights Inc.

Retrieved on: 
Wednesday, July 28, 2021
Nutrition, Academic disciplines, Carbohydrate chemistry, Articles, Actuarial science, Compound annual growth rate, Mathematical finance, Carbohydrate, Oligosaccharide

SELBYVILLE, Del., July 28, 2021 /PRNewswire/ -- The global refined functional carbohydrates market value is projected to cross USD 360 Million by 2027, says the latest research study by Global Market Insights Inc.

Key Points: 
  • SELBYVILLE, Del., July 28, 2021 /PRNewswire/ -- The global refined functional carbohydrates market value is projected to cross USD 360 Million by 2027, says the latest research study by Global Market Insights Inc.
  • The beta glucan segment of refined functional carbohydrates is anticipated to witness over 7% CAGR over the forecast period.
  • Some major findings of the refined functional carbohydrates market report include:
    Mannan oligosaccharides demand is projected to register over 9% CAGR over the forecast timeframe.
  • The North America refined functional carbohydrates market is anticipated to witness over 7% CAGR from 2021 to 2027.

DSM acquires next-generation eubiotics platform start-up

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Natural sciences, Physical sciences, Microbiomes, Biomin, Biotechnology, Carbohydrate chemistry, Bacteriology, DSM, Gut microbiota, Shōjo Tsubaki, Midori

DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.

Key Points: 
  • DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
  • Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals.
  • Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.
  • Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group) .

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021
Breastfeeding, Branches of biology, Nutrition, Food and drink, Carbohydrate chemistry, Chemistry, Dairy products, Oligosaccharides, Human milk oligosaccharide, Milk, Breast milk, Infant formula

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Inbiose applies for FDA GRAS approval of four new Human Milk Oligosaccharides

Retrieved on: 
Tuesday, July 6, 2021
Breastfeeding, Branches of biology, Nutrition, Food and drink, Carbohydrate chemistry, Chemistry, Dairy products, Oligosaccharides, Human milk oligosaccharide, Milk, Breast milk, Infant formula

Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.

Key Points: 
  • Inbiose will also file for Novel Food approval of these HMOs by the European Commission (EFSA) in the coming weeks and is preparing a global regulatory roll-out.
  • Inbiose has been developing a wide range of human-identical milk oligosaccharides that can be industrially produced by sustainable fermentation processes.
  • Inbiose is currently developing its next generation HMOs that will permit infant formula to better replicate the composition of breast milk.
  • Inbiose is a Belgium-based biotech company focused on the research, development and commercialization of specialty carbohydrates, including human milk oligosaccharides.

Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute

Retrieved on: 
Monday, June 28, 2021
Technology, Nanotechnology, Biotechnology, Health, University, Pharmaceutical, Other Science, Science, Education, Chemistry, Physical sciences, Carbohydrate chemistry, Natural sciences, Glycomics, Carbohydrates, BTI, Glycan

Waters Corporation (NYSE:WAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR).

Key Points: 
  • Waters Corporation (NYSE:WAT) today announced an expansion of its joint work with the Bioprocessing Technology Institute (BTI), a research institute of Singapore's Agency for Science, Technology and Research (A*STAR).
  • Isomerism of both glycans and metabolites is particularly troublesome and can be tackled using Waters advanced instruments.
  • Our aim is to make data interpretation easier and faster for scientists to accelerate discovery, for conventional biologics and novel therapeutics.
  • Our work with BTI spans multiple successful collaborations in the realm of glycomics and bioprocessing research, said David Curtin, Vice President of Asia Pacific, Waters Corporation.

New, biological, and safer soaps

Retrieved on: 
Wednesday, May 19, 2021
Pseudomonadales, Gram-negative bacteria, Microbiology, Bioremediation, Biology, Physical sciences, Carbohydrate chemistry, Glycolipids, Surfactant, Pathogenic bacteria, Rhamnolipid, Pseudomonas aeruginosa

Biosurfactants, produced by bacteria, are safer and can replace synthetic surfactants.\nRhamnolipid molecules are some of the safest surfactants known and are particularly attractive, thanks to their biodegradability, minimal toxicity, and amenability to be produced from industrial waste.

Key Points: 
  • Biosurfactants, produced by bacteria, are safer and can replace synthetic surfactants.\nRhamnolipid molecules are some of the safest surfactants known and are particularly attractive, thanks to their biodegradability, minimal toxicity, and amenability to be produced from industrial waste.
  • They are made using Pseudomonas aeruginosa, a pathogenic bacterium harmful to humans.\n"If we want to fully gain the benefits of rhamnolipids, we need to grow these pathogenic bacteria on a huge scale.
  • And because that\'s a health risk, the industry is looking for alternatives," explained Professor Gauthier.
  • The INRS community includes more than 1,500 students, postdoctoral fellows, faculty members, and staff.\n'

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, Neuraminidase, BioCryst Pharmaceuticals, XC2, Viral neuraminidase

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Report First Quarter 2021 Financial Results on May 6

Retrieved on: 
Thursday, April 22, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, XC2, Conference call

b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434.
  • A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com .
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Wednesday, April 7, 2021
Branches of biology, Chemistry, Neuraminidase inhibitors, Natural sciences, Carbohydrate chemistry, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, Viral neuraminidase, Enzyme

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the companys website at www.biocryst.com .